Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
- PMID: 21963517
- DOI: 10.1016/j.jhep.2011.07.033
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
Comment on
-
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.Clin Cancer Res. 2011 Apr 1;17(7):1973-83. doi: 10.1158/1078-0432.CCR-10-2011. Epub 2011 Feb 24. Clin Cancer Res. 2011. PMID: 21349999 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources